Background: The ubiquitin-proteasome system (UPS) plays a pivotal role in tumorigenesis. Components of the UPS have recently been implicated in breast cancer progression. In the present study, we sought to explore the prognostic and/or predictive significance of UBE2C messenger RNA (mRNA) expression on disease-free survival (DFS) and overall survival (OS) in high-risk operable breast cancer patients.
introduction
Breast cancer is a significant cause of morbidity and mortality worldwide. Adjuvant chemotherapy improves disease-free survival (DFS) and overall survival (OS) in patients with breast cancer at high risk for relapse. However, this happens at a cost of substantial toxicity. To improve the therapeutic ratio, research efforts focus on the identification of prognostic/ predictive biomarkers.
The cell cycle transition through the mitotic phase requires the timely degradation of key regulatory molecules, such as securin and cyclin B [1, 2] . This highly organized process is regulated by ubiquitin activating (E1), conjugating (E2) and ligating (E3) enzymes, which covalently bind ubiquitin to substrates, targeting them for destruction by the 26S proteasome [3] . Securin and cyclin B ubiquitination requires the E2-conjugating enzyme UBE2C and E3 ligase proteins, which are components of a large multisubunit complex, called the anaphase-promoting complex/cyclosome (APC/C). Based on these data, mutation of the active site cysteine residue of UBE2C results in a dominant negative phenotype that confers metaphase arrest, showing that the UBE2C protein is essential for cell cycle progression [4] .
Despite the evidence demonstrating that UBE2C is associated with cell cycle regulation, the potential involvement of UBE2C in cancer development has only been recently demonstrated.
The levels of UBE2C transcripts have been found to be highly up-regulated in several cancers, such as ovarian [5] and metastatic prostatic adenocarcinomas [6] . A comparison of the expression levels of 17 ubiquitin genes in normal and cancer tissues identified UBE2C as the most specific cancer-associated gene, while overexpression of UBE2C in NIH3T3 cells resulted in increased proliferative activity [7] . An analysis of transcript levels in 151 cancers of diverse anatomic origins and 35 corresponding normal tissues identified expression of UBE2C as the most significantly elevated in tumors of multiple sites and this was attributed at least in part, to genomic amplification of the UBE2C locus [8] . In addition, selective silencing of UBE2C by RNA interference, in combination with TRAIL/DR5 agonistic antibodies, led to increased cell death in neoplastic but not nonmalignant human cells [8] .
Ki67 is a known marker of cell proliferation and many studies have shown a good correlation between tumor grade and Ki67 [9, 10] . Recently, there has been increased interest in assessing Ki67 as a prognostic and/or predictive marker in breast cancer [11] . The development of new genetic tests, such as Oncotype Dx, emphasizes the role of proliferative markers since many of the genes tested reflect the proliferative status of the tumor [12] . Furthermore, in the St Gallen International Expert Consensus, the panel recommended use of proliferation markers along with traditional parameters when choosing the appropriate systemic treatment of early breast cancer [13] .
Breast cancer is a heterogeneous disease and validated prognostic biomarkers are in great need. In the present study, we sought to explore the prognostic/predictive significance of UBE2C on DFS and OS in high-risk operable breast cancer patients.
materials and methods

patient population
This was a retrospective translational research study among 595 patients who had been enrolled in a prospective clinical trial (HE10/97). Accordingly, collection of formalin-fixed paraffin-embedded (FFPE) primary tumor tissue samples was possible in 313 patients only due to logistical/organizational barriers. The fixation agent used for all samples was 10% neutral-buffered formalin for at least 6 h. The HE10/97 trial randomized 595 high-risk (T 1-3 N 1 M 0 or T 3 N 0 M 0 ) breast cancer patients, between 1997 and 2000, to receive either four cycles of epirubicin (E) followed by four cycles of intensified CMF (cyclophosphamide, methotrexate and 5-fluorouracil) combination chemotherapy (E-CMF) or three cycles of epirubicin followed by three cycles of paclitaxel (Taxol, T, Bristol-Myers Squibb, Princeton, NJ) and three cycles of intensified CMF (E-T-CMF). The trial was included in the Australian New Zealand Clinical Trials Registry (ANZCTR) and allocated the following registration number: ACTRN12611000506998. Chemotherapy cycles were administered every 2 weeks and patients received granulocyte colony-stimulating factor support. The trial was approved from the Bioethics Committee of the Aristotle University of Thessaloniki and patients provided written informed consent before enrollment. All participating patients also signed informed consent for research use of their biologic material. The results of the HE10/97 study have been recently reported [14] . Primary tumor diameter and axillary nodal status were obtained from the pathology report. Nottingham Prognostic Index (NPI) was calculated according to Galea et al. [15] . Histological grade was evaluated according to the Scarff, Bloom and Richardson system.
immunohistochemistry and FISH studies
Estrogen/progesterone receptor (ER/PgR) [16] , human epidermal growth factor receptor 2 (HER2) [17] and Ki67 [18] protein expression were assessed centrally by immunohistochemistry (IHC), as preciously described, using tissue microarrays. HER2 gene amplification was also assessed by FISH [17] . Due to space limitations, complete methods are given in the Supplementary Data (available at Annals of Oncology online).
RNA isolation and quantitative RT-PCR
Hematoxylin-eosin sections from all available FFPE tissue specimens were evaluated histologically by a certified pathologist who recorded percentage of tumor cell content in each one. Before RNA isolation, macrodissection of tumor areas was carried out in most of the FFPE sections with <50% tumor cell content. The tumor cell content was >30%, in practically all (97%) of the samples, and >50% in the majority (76%) of the samples. More than one FFPE section was used for RNA extraction when the tumor surface of a given sample was <0.25 cm 2 .
Sufficient RNA was isolated from 313 FFPE specimens followed by quantitative RT-PCR (qRT-PCR), as previously described [19] . From each FFPE section or macrodissected tissue fragments (10-lm thick), RNA was isolated using a standardized fully automated isolation method for total RNA from FFPE tissue, based on silica-coated magnetic beads (VERSANT Tissue Preparation Reagents; Siemens Healthcare Diagnostics, Tarrytown, NY) in combination with a liquid handling robot, as previously described in detail [20] . The method involves extraction-integrated deparaffinization and DNase I digestion steps. DNA-free total RNA was eluted with 100 ll elution buffer and stored in 280°C. The quality and quantity of RNA were checked by measuring RPL37A expression as a surrogate for amplifiable messenger RNA (mRNA) by qRT-PCR.
One-step qRT-PCR was applied for the assessment of UBE2C mRNA expression by using gene-specific TaqManÒ-based assays. Forty cycles of nucleic acid amplification were applied and the cycle threshold (CT) values of the target gene were identified. CT values were normalized by subtracting the CT value of the housekeeping gene RPL37A from the CT value of the target gene (DCT). RNA results were then reported as 402DCT values, which correlate proportionally to the mRNA expression level of the target gene. Samples with average RPL37A CT values <32 were considered eligible for analysis.
Expression of the target gene, as well as the reference gene RPL37A, was assessed in triplicate by qRT-PCR using the SuperScript III PLATINUM One-Step Quantitative RT-PCR System with ROX (Invitrogen, Karlsruhe, Germany) in an ABI PRISM 7900HT (Applied Biosystems, Darmstadt, Germany) [21] . The lengths of the amplicons detected by the UBE2C and RPL37A assays were 95 and 65 bp, respectively, with PCR efficiencies [E = 1 (10-slope) ] of 81.5% and 86.0%, respectively. A commercially available human reference RNA (Stratagene qPCR Human Reference Total RNA; Agilent Technologies, Waldbronn, Germany) was used as positive control. No-template controls were assessed in parallel to exclude contamination.
The Primer/Probe (carboxyfluorescein/tetramethylrhodamine [FAM/ TAMRA]-labeled) sets used for amplification of the target and reference genes were the following (5#/3#):
DFS was defined as time from study entry to first tumor recurrence, secondary neoplasm or death from any cause [22] . OS was measured from study entry until death from any cause. Surviving patients were censored at the date of last contact. The prognostic value of mRNA expression for the UBE2C gene was examined in terms of OS and DFS using the quartiles of the mRNA distribution as possible thresholds. In case a cut-off was of prognostic significance, it was used to dichotomize tumor expression into low and high. The Fisher's exact test or Pearson's chi-square test were used for group comparison of categorical data, while for continuous data the Mann-Whitney test was used. Kaplan-Meier curves and log-rank tests were used for comparing time to event distributions.
Cox proportional hazard regression analyses, adjusted for treatment, were carried out for UBE2C mRNA expression, Ki67 protein expression and NPI to assess prognostic significance on OS and DFS. Predictive significance of UBE2C expression was examined by interaction tests between UBE2C and treatment group using Cox regression models. In multivariate analysis, a backward selection procedure with a removal criterion P > 0.10 based on the likelihood ratio test was carried out to identify significant clinicopathologic variables among the following: age, menopausal status (pre versus post), tumor grade (I to II versus III to undifferentiated), Ki67 protein expression (low versus high), NPI score values (as a continuous variable), tumor size (£2 versus 2-5 versus >5 cm), number of positive axillary nodes (0-3 versus ‡4), ER/PgR status (negative versus positive), HER2 status (negative versus positive), adjuvant hormone therapy (yes versus no), adjuvant radiotherapy (yes versus no), type of operation (modified radical mastectomy versus breast-conserving surgery) and time interval from breast surgery (<2 versus 2-4 versus >4 weeks). Treatment group (E-T-CMF versus E-CMF) and UBE2C mRNA expression (binary or continuous) were kept in the final model, in order to examine whether UBE2C added independent prognostic information in the presence of treatment and significant parameters.
Results of this study were presented according to reporting recommendations for tumor marker prognostic studies [23] . This study is prospective-retrospective as described in Simon et al. [24] . The SPSS software (SAS Institute Inc., Cary, NC) was used for statistical analysis (SPSS for Windows, version 15.0; SPSS Inc.).
A longer version of the materials and methods section is available as supplemental Materials and Methods at Annals of Oncology online.
results
patient characteristics
Basic clinical and pathological characteristics of patients (supplemental Table S2 , available at Annals of Oncology online) were well balanced according to adjuvant chemotherapy, except for NPI (P = 0.031) and grade (P = 0.009). The latter is in agreement to corresponding results presented previously [14] . For the entire patient population, the median patient age was 50 years (range 22-78 years) and the median NPI score was 5.8 (range 3.2-8.4). The majority of patients (centrally assessed by IHC and FISH in the case of HER2) were ER/PgR positive (80%), HER2 negative (73%) and Ki67 positive (83%) and had received adjuvant radiation therapy (82%) and hormonal therapy (92%).
normalized mRNA expression of UBE2C gene expression
The distribution of tumor samples according to the normalized expression of mRNA encoding for UBE2C is shown in Figure 1 . The median value for UBE2C mRNA expression was 33.8, the 25th percentile was 32.6 and the 75th percentile was 34.6, with a range of 28.4-37.6. The 25th percentile was found to be the optimal cut-off for UBE2C mRNA expression.
association of UBE2C mRNA expression with clinicopathologic parameters
High UBE2C mRNA expression was significantly associated with high tumor grade (58% in high UBE2C tumors versus 24% in low UBEC2 tumors, P < 0.001). In addition, ER/ PgR-negative tumors, HER2-positive tumors, high Ki67 protein expression and higher NPI median scores were more frequent in the high UBE2C mRNA expressing group than in the low-expressing group (23% versus 10%, P = 0.022; 32% versus 10%, P = 0.001; 87% versus 72%, P = 0.004; and 6.2% versus 5.5%, P < 0.001, respectively). There were no other significant associations between UBE2C mRNA expression and selected clinicopathologic parameters (Table 1) .
prognostic/predictive value of UBE2C mRNA expression
Survival status of all patients was updated in October 2007. The median follow-up time was 98 months (range 7-126 months). During this time, 110 patients had developed documented disease relapse and 80 patients had died. The 5-year OS rate was 84% [95% confidence interval (CI) 79% to 88%], while the 5-year DFS rate was 71% (95% CI 66% to 76%).
Among the quartiles of the UBE2C mRNA distribution, the 25th percentile distinguished two populations of significantly different prognosis, as stated above. High expression of UBE2C (above the 25th percentile) was significantly associated with reduced OS (log-rank, P = 0.003) and DFS (log-rank, P = 0.002). Kaplan-Meier curves for OS and DFS according to UBE2C mRNA expression are shown in Figure 2 . More specifically, among the 78 low UBE2C cases, 10 patients (13%) died and 17 (22%) relapsed, while among 235 high UBE2C cases, 70 deaths (30%) and 93 relapses (40%) occurred. Five-year survival and DFS rates were 94% and 86% in the low UBE2C tumors, respectively, versus 80% and 66% in the high UBE2C tumors, respectively. Cox regression analysis, adjusted for treatment, revealed that high UBE2C mRNA expression was associated with higher risk for death [hazard ratio (HR) = 1.18, 95% CI 0.76-1.84, Wald's P = 0.005] and relapse (HR = 2.14, HR = 1.15, 95% CI 1.02-1.30, Wald's P = 0.018). UBE2C mRNA expression was not predictive for benefit from the addition of paclitaxel to the E-CMF treatment either for DFS (test for interaction, P = 0.56) or OS (P = 0.79).
multivariate analysis
In the multivariate Cox regression analysis, shown in Table 2 , UBE2C retained its prognostic significance for DFS (HR = 1.82, 95% CI 1.04-3.21, Wald's P = 0.037), while in terms of OS, this association was marginally significant (HR = 2.12, 95% CI 1.02-4.48, P = 0.05). High Ki67 protein expression was found to be associated with higher risk for death (HR = 3.43, 95% CI 1.23-9.53, P = 0.018) but not for relapse (P = 0.065). Positive hormonal receptor status was a favorable prognostic factor for both OS and DFS, while four or more positive nodes had an adverse prognostic impact on DFS but not on OS. Higher NPI scores were not significant in the multivariate model; they were however associated with higher risk for death and relapse in the univariate analysis (P < 0.001 for both). The continuous UBE2C mRNA expression values were not significant either for OS or DFS (P = 0.25 and 0.56, respectively) when included in the final model.
discussion
In the present study, we sought to determine the prognostic significance of UBE2C mRNA in a retrospective cohort of high-risk breast cancer patients treated with a dose-dense sequential chemotherapy protocol. We demonstrated that UBE2C mRNA levels inversely correlated with DFS and OS times. High UBE2C mRNA expression was significantly associated with high Ki67 and NPI scores when adjusted only for treatment. UBE2C mRNA expression appears to be a stronger prognostic indicator than Ki67 and NPI since high UBE2C did retain its independent prognostic significance in multivariate analysis for increased risk for both death and relapse.
Jezequel et al. [25] conducted a retrospective study in nodepositive breast cancer to identify gene expression signatures associated with metastasis-free survival (MFS). The patient cohort was included in the FEC100 (5-fluorouracil 500 mg/m 2 , epirubicin 100 mg/m 2 and cyclophosphamide 500 mg/m 2 ) or the FEC + docetaxel arms of two multicentric prospective adjuvant clinical trials. Using nylon microarrays containing 8032 unique complementary DNA sequences, representing 5776 distinct genes, the authors obtained gene expression profiles for 252 of these patients and identified a genomic signature of metastatic relapse after adjuvant treatment with the FEC100 regimen. UBE2C was one of the 14 selected genes, whose high expression was strongly associated with metastatic relapse.
UBE2C was found to be up-regulated in breast cancer tissues compared with normal breast tissues in the study by Berlingieri et al. [26] . The authors demonstrated, by tissue microarray immunohistochemical studies, a significant difference (P = 0.0001) in the mean percentage of UBE2C-stained cells between benign (0.22%) and malignant (11.01%) neoplastic lesions. High UBE2C protein expression was associated with intense Ki67 staining (P = 0.015) and HER2 positivity (P = 0.092), but there was no association between the [26] , the UBE2C IHC score had a significant impact both on MFS and OS (HR = 6.79, P = 0.002; HR = 7.14, P = 0.009, respectively). The prognostic power of UBE2C protein expression was stronger than that of Ki67 (and close to that of NPI). Furthermore, multivariate analyses including NPI showed that, contrary to Ki67, UBE2C protein expression remained an independent prognostic factor, both for MFS (adjusted P = 0.02) and OS (adjusted P = 0.04). The conflicting results reported using UBE2C IHC scores could be attributed to the technical problems inherent to conventional IHC, such as the semiquantitative nature of the assay, subjectivity of pathologistbased scoring and variability in staining protocols. In this context, our study also demonstrated that RNA extraction from FFPE tissue specimens is feasible and enables the quantitative determination of gene expression levels using qRT-PCR. Studies have shown that several components of the ubiquitin-proteasome system (UPS) are related to breast carcinogenesis and a dismal outcome in breast cancer [27] [28] [29] . Furthermore, elevated proteasome activity has been directly associated with overexpression of the UPS components (ubiquitin enzymes and proteasomal subunits) [28] . Taken together, these results indicate that UBE2C levels are reflective of proteasome activity, which is elevated in breast cancer with rapid growth rate conferring poor prognosis.
The recognition of the pivotal role of the proteasome in cell cycle regulation and carcinogenesis led to the discovery of proteasome inhibitors, a novel and promising class of anticancer agents [30] [31] [32] . Bortezomib, a proteasome inhibitor, has been approved by the Food and Drug Administration for the treatment of relapsed and refractory multiple myeloma. Bortezomib as singe agent had no activity in breast cancer. It is possible that patient selection should be based on UBE2C mRNA levels, similar to the paradigm of antiestrogens and ERs. Another approach could be the combination of bortezomib with chemotherapy [33] or trastuzumab. We found an association between UBE2C mRNA expression and HER2 status. The relation between HER2 gene amplification and overexpression of proteasome subunits has been reported previously [27] . A functional link may exist between increased proteasome activity and HER2 amplification, and therefore Figure 2 . High mRNA expression of UBE2C (above the 25th percentile) was significantly associated with (A) shorter OS (log-rank, P = 0.003) and (B) shorter DFS (log-rank, P = 0.002). DFS, disease-free survival; OS, overall survival. 
